Clinical trialNCT06994676RecruitingPhase 1Interventional

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

SponsorCrossbow Therapeutics, Inc.Enrollment72AML - Acute Myeloid LeukemiaChronic Myeloid LeukemiaChronic Myelomonocytic Leukemia (CMML)High-risk Myelodysplastic Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Briggs Morrison, MD
Crossbow Therapeutics, Inc.
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Brian Ball, MD
Recruiting
Stanford Medical Center
Palo Alto, California, United States
Gabriel Mannis, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
David Sallman, MD
Recruiting
Northwestern Medicine
Chicago, Illinois, United States
Jessica Altman, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Evan Chen, MD
Recruiting
Washington University in St. Louis
St Louis, Missouri, United States
John DiPersio, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Eytan Stein, MD
Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Gina Keiffer, MD
Recruiting
Sarah Cannon Cancer Institute
Nashville, Tennessee, United States
Stephen Strickland, MD
Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Somedeb Ball, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Ghayas Issa, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CBX-250

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Jul 2025
Primary completion: 31 Jan 2027
Completion: 30 Jun 2027
Last update posted: 16 Mar 2026
Registered enrollment: 72
Registry id: NCT06994676

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.